RADNOR,
Pa., Sept. 7, 2023 /PRNewswire/ -- NRx
Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the
"Company"), a clinical-stage biopharmaceutical company, today
announced that Stephen Willard,
J.D., Chief Executive Officer and Dr. Jonathan Javitt, Chief Scientist of NRx
Pharmaceuticals, will present a company overview at the H.C.
Wainwright 25th Annual Global Investment Conference. The
presentation is scheduled for Tuesday,
September 12, 2023, at 5:00PM
ET. The in-person venue for the event is the Lotte New
York Palace Hotel in New York City
located at 455 Madison Avenue. Virtual participation will be
staged simultaneously with over 550 company presentations scheduled
as live feed or available on-demand.
Management will be available for one-on-one meetings at
conference attendees as well.
A webcast and subsequent archived replay will be available on
the Company's website at
https://ir.nrxpharma.com/news-events/ir-calendar. The replay will
be available for 90 days after the event.
About NRX-101
NRX-101, a fixed dose combination of D-cycloserine and
lurasidone, has been granted Fast Track Designation, Breakthrough
Therapy Designation, a Special Protocol Agreement, and a Biomarker
Letter of Support from the FDA for S-TRBD. Additionally, the
product is being developed in chronic pain and PTSD.
Up to 50% of individuals with bipolar disorder attempt suicide
over their lifetime, and estimates indicate that up to 20% may
succumb to suicide. The only FDA-approved treatment for patients
with treatment-resistant suicidal bipolar depression remains
electroconvulsive therapy.
Conventional antidepressants can increase the risk of suicide in
certain patients; hence their labels contain a warning to that
effect. NRX-101 is a patented, oral, fixed dose combination of
D-cycloserine and lurasidone, neither of which has shown addiction
potential in preclinical models. Based on the results of a Phase 2
proof-of-concept study, NRX-101 received Breakthrough Therapy
Designation from the FDA for the treatment of severe bipolar
depression in patients with ASIB after initial stabilization with
ketamine or other effective therapy.
NRX-101 is one of the first oral antidepressants currently in
late-stage clinical studies targeting the NMDA-receptor in the
brain, which represents potentially a key new mechanism to treat
depression with and without suicidality, as well as chronic pain,
PTSD and other indications.
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical
company developing therapeutics based on its NMDA platform for the
treatment of central nervous system disorders, specifically
suicidal bipolar depression, chronic pain and PTSD. The Company's
lead program NRX-101, an oral, fixed-dose combination of
D-cycloserine and lurasidone, targets the brain's
N-methyl-D-aspartate (NMDA) receptor and is being investigated in a
Phase 2b/3 clinical trial for
suicidal treatment-resistant bipolar depression (S-TRBD), which
includes patients with both acute and sub-acute suicidality, an
indication for which the only approved treatment is electroshock
therapy. The Company has partnered with Alvogen Pharmaceuticals,
who owns the worldwide rights to NRX-101 for treatment of S-TRBD,
to help bring NRX-101 to a global population of patients with unmet
medical need. NRx Pharmaceuticals is currently exploring NRX-101's
potential to act as a non-opioid chronic pain treatment option and
is continuing to plan to enroll patients in an Israeli-based trial
of patients suffering from post-traumatic stress disorder with
depression and suicidality.
About H.C. Wainwright & Co.
H.C. Wainwright is a full‐service investment bank dedicated to
providing corporate finance, strategic advisory and related
services to public and private companies across multiple sectors
and regions. H.C. Wainwright & Co. also provides
research and sales and trading services to institutional
investors. According to Sagient Research Systems,
H.C. Wainwright's team is ranked as the #1 Placement Agent in terms
of aggregate CMPO (confidentially marketed public offering), RD
(registered direct offering) and PIPE (private investment in public
equity) executed cumulatively since 1998. For more information
visit H.C. Wainwright & Co. on the web at
www.hcwco.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-to-present-at-the-hc-wainwright-25th-annual-global-investment-conference-301920261.html
SOURCE NRx Pharmaceuticals, Inc.